美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Pharmaceuticals ETF

66.94

-0.8100-1.20%

盤後：66.94-0.00220.00%19:30 EDT

成交量：54.93萬

成交額：3,677.35萬

市值：5.72億

市盈率：25.93

高：67.74

開：67.74

低：66.78

收：67.75

52周最高：74.35

52周最低：45.82

股本：855.03萬

流通股本：855.03萬

量比：3.11

換手率：6.42%

股息：0.34

股息率：0.51%

每股收益(TTM):2.58

每股收益(LYR):-0.1280

淨資產收益率：42.40%

總資產收益率：0.26%

市淨率：1.34

市盈率(LYR):-522.90

資料載入中...

總覽公司新聞資訊公告

復星醫藥：控股子公司與Sandoz AG達成至多10款生物類似藥許可合作，首批3款產品首付款及里程碑款至多2.37億美元

重塑全球藥企版圖！阿斯利康擬洽購百時美施貴寶，或締造史上最大醫藥併購案

重塑全球藥企版圖！阿斯利康(AZN.US)擬洽購百時美施貴寶(BMY.US)，或締造史上最大醫藥併購案

三星生物製劑與歐加農將在澳大利亞推出新型生物類似藥。

復宏漢霖(02696)：西妥昔單抗注射液生物類似藥HLX05-N在轉移性結直腸癌(mCRC)患者中的1期臨床研究於中國境內完成首例患者給藥

景澤生物三次遞表港交所，核心產品均為生物類似藥，投後估值約32.1億元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/XPH/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"XPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","market":"US","secType":"STK","nameCN":"SPDR S&P Pharmaceuticals ETF","latestPrice":66.94,"timestamp":1789761600000,"preClose":67.75,"halted":0,"volume":549335,"hourTrading":{"tag":"盘后","latestPrice":66.9378,"preClose":66.94,"latestTime":"19:30 EDT","volume":332439,"amount":22252753.7564,"timestamp":1789774205794,"change":-0.0022,"changeRate":-0.000033,"amplitude":0.000033},"delay":0,"changeRate":-0.011955719557195606,"floatShares":8550270,"shares":8550270,"eps":2.581957,"marketStatus":"休市中","change":-0.81,"latestTime":"09-18 16:00:00 EDT","open":67.74,"high":67.74,"low":66.78,"amount":36773468.209649995,"amplitude":0.01417,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":2.581957,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":67.75,"sharesOutstanding":5750270,"nav":67.859224,"aum":580214690.85,"dividendRate":0.005079,"bidAskSpread":0.001861,"preHourTrading":{"tag":"盘前","latestPrice":67.75,"preClose":67.75,"latestTime":"07:37 EDT","volume":1,"amount":67.75,"timestamp":1789731462581,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":66.9378,"preClose":66.94,"latestTime":"19:30 EDT","volume":332439,"amount":22252753.7564,"timestamp":1789774205794,"change":-0.0022,"changeRate":-0.000033,"amplitude":0.000033},"volumeRatio":3.107928132550368,"impliedVol":0.0618,"impliedVolPercentile":0.0398},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","floatShares":8550270,"roa":"0.26%","roe":"42.40%","lyrEps":-0.128016,"volumeRatio":3.107928132550368,"shares":8550270,"dividePrice":0.34,"high":67.74,"amplitude":0.01417,"preClose":67.75,"low":66.78,"week52Low":45.82,"pbRate":"1.34","psRate":"261.25","week52High":74.345,"institutionHeld":0,"latestPrice":66.94,"eps":2.581957,"divideRate":0.005079,"volume":549335,"delay":0,"ttmEps":2.581957,"open":67.74,"prevYearClose":56.01,"prevWeekClose":67.51,"prevMonthClose":70.62,"prevQuarterClose":66.27,"fiveDayClose":67.51,"twentyDayClose":72.29,"sixtyDayClose":64.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XPH\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"XPH","amount":0.04164,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-23","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-23"},{"date":"2026-06-22","symbol":"XPH","amount":0.059045,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2026-03-23","symbol":"XPH","amount":0.060954,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-25","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-25"},{"date":"2025-12-22","symbol":"XPH","amount":0.113024,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XPH","amount":0.102634,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XPH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.091273,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.026956,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.085023,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.07227,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.019429,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XPH\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660219103","title":"復星醫藥：控股子公司與Sandoz AG達成至多10款生物類似藥許可合作，首批3款產品首付款及里程碑款至多2.37億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660219103","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660219103?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 07:48","pubTimestamp":1786924110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XPH","SILJ","SLVR","LU2473716301.USD","IBB","LU1992135399.USD","AG","LU1992135472.HKD","LU2322448791.USD","LU2272731782.SGD","SLVX","LU2272731865.HKD","SLJY","BK4585","LU2272731600.USD","LU2322448957.HKD","IE00B5TLWC47.USD","BK4588","PPH","BK4210"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346866","title":"重塑全球藥企版圖！阿斯利康擬洽購百時美施貴寶，或締造史上最大醫藥併購案","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346866","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656346866?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 07:30","pubTimestamp":1785713456,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，阿斯利康已就收购百时美施贵宝展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。阿斯利康市值超过百时美施贵宝百时美施贵宝正为其部分最核心产品面临专利保护到期做准备，包括抗凝药艾乐妥与抗癌药欧狄沃。两款产品合计约占百时美施贵宝销售额的一半。上周，百时美施贵宝公布季度销售额 130 亿美元，创历史最高。阿斯利康目前是伦敦证券交易所市值第二大的公司。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"重塑全球药企版图！阿斯利康拟洽购百时美施贵宝，或缔造史上最大医药并购案","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK4559","LU2456880835.USD","LU2237443549.SGD","LU0456855351.SGD","BK4534","IE00B5TLWC47.USD","IE00BFTCPJ56.SGD","FTXH","IHE","LU2237443978.SGD","LU1585245621.USD","PILL","LU2360032135.SGD","LU2237443622.USD","FHLC","LU0432979614.USD","LU2473716301.USD","MEDI","LU1032466523.USD","IE00BSNM7G36.USD","LU2237443465.HKD","LU2272731600.USD","IEHS","LU2237443382.USD","IE0009355771.USD","LU1323610961.USD","LU2125154778.USD","RXD","CURE","AZNH","LU0029864427.USD","SYNB","LU1291159041.SGD","LU0096364046.USD","LU2242652126.USD","AZN","LU1093756325.SGD","XPH","XBIX","RXL","LU1992135472.HKD","IE00BJT1NW94.SGD","JHMH","PPH","IE00B3T34201.USD","LU0061475181.USD","BMY","LU1718418525.SGD","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656468693","title":"重塑全球藥企版圖！阿斯利康(AZN.US)擬洽購百時美施貴寶(BMY.US)，或締造史上最大醫藥併購案","url":"https://stock-news.laohu8.com/highlight/detail?id=2656468693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656468693?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 07:25","pubTimestamp":1785713101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FHLC","MEDI","XPH","FXH","LU0456855351.SGD","LU2272731782.SGD","IHE","PILL","LU2089984988.USD","AZNH","LU2596442595.SGD","XBIX","IE0009355771.USD","BMY","IE00BFTCPJ56.SGD","FTXH","LU1032466523.USD","LU0306807586.USD","IE0002141913.USD","LU1868836914.USD","IE00BSNM7G36.USD","RXD","LU0058720904.USD","BK4588","LU1670710661.SGD","IE00BFXG1179.USD","LU1989771016.USD","LU2125154935.USD","BK4581","BK4534","SYNB","LU0985481810.HKD","LU0096364046.USD","IE00B5TLWC47.USD","CURE","LU1074936037.SGD","IE00BJJMRZ35.SGD","JHMH","LU0237698245.USD","LU2456880835.USD","AZN","LU1868837136.USD","LU0029864427.USD","LU1267930573.SGD","IE00B3T34201.USD","LU0225771236.USD","PPH","RXL","IEHS","LU1670711123.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651495621","title":"三星生物製劑與歐加農將在澳大利亞推出新型生物類似藥。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651495621","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651495621?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 04:04","pubTimestamp":1784145897,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B5TLWC47.USD","LU1992135399.USD","LU2272731865.HKD","LU2473716301.USD","IBB","LU1992135472.HKD","LU2322448791.USD","BK4585","PPH","XPH","LU2272731600.USD","BK4588","LU2322448957.HKD","EMXC","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964779","title":"復宏漢霖(02696)：西妥昔單抗注射液生物類似藥HLX05-N在轉移性結直腸癌(mCRC)患者中的1期臨床研究於中國境內完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964779","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649964779?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 17:27","pubTimestamp":1783502848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的西妥昔单抗注射液生物类似药HLX05-N在转移性结直肠癌患者中的1期临床研究于中国境内完成首例患者给药。本研究是一项在KRAS/NRAS野生型且BRAF V600E无突变的转移性结直肠癌参与者中，比较HLX05-N与美国及欧盟来源Erbitux联合化疗 治疗的多中心、随机、双盲、平行对照1期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","HK0000306701.USD","IE00B5TLWC47.USD","LU1992135399.USD","BK1161","HK0000320223.HKD","LU2322448957.HKD","LU2272731782.SGD","LU2473716301.USD","IBB","LU2272731600.USD","BK4585","BK4588","02696","LU2272731865.HKD","HK0000165453.HKD","HK0000306685.HKD","XPH","LU2322448791.USD","LU1992135472.HKD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649462386","title":"景澤生物三次遞表港交所，核心產品均為生物類似藥，投後估值約32.1億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649462386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649462386?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 18:12","pubTimestamp":1783332779,"startTime":"0","endTime":"0","summary":"一款核心产品已获批上市一年多，尚未产生收入","market":"sg","thumbnail":"https://img2.gelonghui.com/6475f-76e0e400-d516-42c4-bd42-eb561753a368.jpg?guru_height=906&guru_width=1362&guru_size=182799","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/6475f-76e0e400-d516-42c4-bd42-eb561753a368.jpg?guru_height=906&guru_width=1362&guru_size=182799"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5471876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU1992135472.HKD","LU2272731600.USD","LU2322448957.HKD","IE00B5TLWC47.USD","PPH","BK4585","XPH","HEXmain","LU2473716301.USD","LU2322448791.USD","BK4588","LU2272731865.HKD","IPOS","LU2272731782.SGD","LU1992135399.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":26,"code":"91000000","status":"200"}]}}